100 related articles for article (PubMed ID: 1337114)
1. [Vasopressin (ADH)].
Hirai A; Uchida D; Yoshida S
Nihon Rinsho; 1992 Dec; 50(12):2893-900. PubMed ID: 1337114
[TBL] [Abstract][Full Text] [Related]
2. Molecular cloning and expression of a rat V1a arginine vasopressin receptor.
Morel A; O'Carroll AM; Brownstein MJ; Lolait SJ
Nature; 1992 Apr; 356(6369):523-6. PubMed ID: 1560825
[TBL] [Abstract][Full Text] [Related]
3. Cloning and characterization of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipidus.
Lolait SJ; O'Carroll AM; McBride OW; Konig M; Morel A; Brownstein MJ
Nature; 1992 May; 357(6376):336-9. PubMed ID: 1534150
[TBL] [Abstract][Full Text] [Related]
4. Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.
Serradeil-Le Gal C; Lacour C; Valette G; Garcia G; Foulon L; Galindo G; Bankir L; Pouzet B; Guillon G; Barberis C; Chicot D; Jard S; Vilain P; Garcia C; Marty E; Raufaste D; Brossard G; Nisato D; Maffrand JP; Le Fur G
J Clin Invest; 1996 Dec; 98(12):2729-38. PubMed ID: 8981918
[TBL] [Abstract][Full Text] [Related]
5. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.
Yamamura Y; Nakamura S; Itoh S; Hirano T; Onogawa T; Yamashita T; Yamada Y; Tsujimae K; Aoyama M; Kotosai K; Ogawa H; Yamashita H; Kondo K; Tominaga M; Tsujimoto G; Mori T
J Pharmacol Exp Ther; 1998 Dec; 287(3):860-7. PubMed ID: 9864265
[TBL] [Abstract][Full Text] [Related]
6. Blocking effects of V1 (OPC-21268) and V2 (OPC-31260) antagonists on the negative inotropic response to vasopressin in isolated dog heart preparations.
Furukawa Y; Takayama S; Ren LM; Sawaki S; Inoue Y; Chiba S
J Pharmacol Exp Ther; 1992 Nov; 263(2):627-31. PubMed ID: 1331408
[TBL] [Abstract][Full Text] [Related]
7. Lithium effectively complements vasopressin V2 receptor antagonist in the treatment of hyponatraemia of SIADH rats.
Kazama I; Arata T; Michimata M; Hatano R; Suzuki M; Miyama N; Sanada S; Sato A; Satomi S; Ejima Y; Sasaki S; Matsubara M
Nephrol Dial Transplant; 2007 Jan; 22(1):68-76. PubMed ID: 16702208
[TBL] [Abstract][Full Text] [Related]
8. Functional characterization of vasopressin V1 and V2 receptors in the rabbit renal cortical collecting duct.
Yoshitomi K; Naruse M; Hanaoka K; Yamamura Y; Imai M; Kurokawa K
Kidney Int Suppl; 1996 Jun; 55():S177-82. PubMed ID: 8743549
[TBL] [Abstract][Full Text] [Related]
9. Effects of receptor blockade on metabolism and renal actions of vasopressin in conscious dogs.
Grove L; Christensen P; Bie P
Acta Physiol Scand; 1998 May; 163(1):93-101. PubMed ID: 9648627
[TBL] [Abstract][Full Text] [Related]
10. Lack of effect of a selective vasopressin V1A receptor antagonist SR 49,059, on potentiation by vasopressin of adrenoceptor-mediated pressor responses in the rat mesenteric arterial bed.
Heinemann A; Horina G; Stauber RE; Pertl C; Holzer P; Peskar BA
Br J Pharmacol; 1998 Nov; 125(6):1120-7. PubMed ID: 9863637
[TBL] [Abstract][Full Text] [Related]
11. A lack of anti-hypertensive effect of an orally effective V1 receptor antagonist, OPC-21268, in end-stage renal disease.
Nakayama M; Yamada K; Nakano H; Miura Y; Suzuki S; Tuchida H; Yoshida S
Clin Nephrol; 1993 Jul; 40(1):58-9. PubMed ID: 8395368
[No Abstract] [Full Text] [Related]
12. [Recent advances in vasopressin receptors and signal transduction system].
Terada Y; Marumo F
Nihon Rinsho; 1993 Oct; 51(10):2655-60. PubMed ID: 8254935
[TBL] [Abstract][Full Text] [Related]
13. Vasopressin promotes cardiomyocyte hypertrophy via the vasopressin V1A receptor in neonatal mice.
Hiroyama M; Wang S; Aoyagi T; Oikawa R; Sanbe A; Takeo S; Tanoue A
Eur J Pharmacol; 2007 Mar; 559(2-3):89-97. PubMed ID: 17275806
[TBL] [Abstract][Full Text] [Related]
14. An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin.
Manning M; Cheng LL; Stoev S; Bankowski K; Przybyiski J; Klis WA; Sawyer WH; Wo NC; Chan WY
J Pept Sci; 1995; 1(1):66-79. PubMed ID: 9222985
[TBL] [Abstract][Full Text] [Related]
15. The effect of OPC-21268, an oral, nonpeptide arginine vasopressin V1 receptor antagonist, on a patient with congestive heart failure.
Miura Y; Yamada K; Nakayama M; Nakano H; Suzuki S; Tsuchida H; Yoshida S
Clin Nephrol; 1993 Jul; 40(1):60-1. PubMed ID: 8395369
[No Abstract] [Full Text] [Related]
16. Biological half-life and organ distribution of [3H]8-arginine vasopressin following administration of vasopressin receptor antagonist OPC-31260.
Molnár AH; Varga C; Janáky T; Tóth G; Tóth G; Farkas J; László F; László FA
Regul Pept; 2007 Jun; 141(1-3):12-8. PubMed ID: 17258819
[TBL] [Abstract][Full Text] [Related]
17. Distinct mechanisms of action of V1 antagonists OPC-21268 and [d(CH2)5Tyr(Me)AVP] in mesangial cells.
Jamil KM; Watanabe T; Nakao A; Okuda T; Kurokawa K
Biochem Biophys Res Commun; 1993 Jun; 193(2):738-43. PubMed ID: 8390252
[TBL] [Abstract][Full Text] [Related]
18. Molecular cloning of the receptor for human antidiuretic hormone.
Birnbaumer M; Seibold A; Gilbert S; Ishido M; Barberis C; Antaramian A; Brabet P; Rosenthal W
Nature; 1992 May; 357(6376):333-5. PubMed ID: 1534149
[TBL] [Abstract][Full Text] [Related]
19. Cloning, functional expression and tissue distribution of human cDNA for the vascular-type vasopressin receptor.
Hirasawa A; Shibata K; Kotosai K; Tsujimoto G
Biochem Biophys Res Commun; 1994 Aug; 203(1):72-9. PubMed ID: 8074728
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a novel nonpeptide vasopressin V(2)-agonist, OPC-51803, in cells transfected human vasopressin receptor subtypes.
Nakamura S; Yamamura Y; Itoh S; Hirano T; Tsujimae K; Aoyama M; Kondo K; Ogawa H; Shinohara T; Kan K; Tanada Y; Teramoto S; Sumida T; Nakayama S; Sekiguchi K; Kambe T; Tsujimoto G; Mori T; Tominaga M
Br J Pharmacol; 2000 Apr; 129(8):1700-6. PubMed ID: 10780976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
